In order to obtain a better understanding of the immunomodulatory effects of different PD-1 pathway inhibitors, we herein compared infection outcomes and immune features of immunosuppressed mice with IPM after (mono)therapy with PD-1/PD-L1 blocking antibodies or non-targeting isotype antibodies. Here, PDCD1 is linked to infection.